FIG 4.

Blocking IgM-mediated complement activation of the classical complement pathway reduces CML of VSV-GP. NHS, hiNHS, or GMEM (w/o) were preincubated with an anti-human IgM antibody (10 μg [A] or the indicated amount [B]) to block the IgM-mediated activation of the classical complement pathway. Subsequently, serum resistance assays were performed using VSV-GP(L929) (A) and VSV-GP(Vero) (B), and viral titers were determined by plaques assays. The data show the results from two independent experiments, with two technical replicates. Mean values are shown, and error bars indicate the SD.